AlgiPharma AS - Product Pipeline Review - 2014

Published: Aug, 2014 | Pages: 22 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

AlgiPharma AS - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'AlgiPharma AS - Product Pipeline Review - 2014', provides an overview of the AlgiPharma AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AlgiPharma AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AlgiPharma AS including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AlgiPharma AS's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the AlgiPharma AS's pipeline products

Reasons to buy

- Evaluate AlgiPharma AS's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AlgiPharma AS in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AlgiPharma AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AlgiPharma AS and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AlgiPharma AS
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AlgiPharma AS and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
AlgiPharma AS Snapshot 4
AlgiPharma AS Overview 4
Key Information 4
Key Facts 4
AlgiPharma AS - Research and Development Overview 5
Key Therapeutic Areas 5
AlgiPharma AS - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
AlgiPharma AS - Pipeline Products Glance 9
AlgiPharma AS - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
AlgiPharma AS - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
AlgiPharma AS - Drug Profiles 12
Oligomer G for Cystic Fibrosis 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Oligomer G for Bacterial Infectious 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Oligomer G for COPD 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Oligomer G for Wounds And Burns 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AlgiPharma AS - Pipeline Analysis 17
AlgiPharma AS - Pipeline Products by Route of Administration 17
AlgiPharma AS - Pipeline Products by Molecule Type 18
AlgiPharma AS - Recent Pipeline Updates 19
AlgiPharma AS - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

List of Tables
AlgiPharma AS, Key Information 4
AlgiPharma AS, Key Facts 4
AlgiPharma AS - Pipeline by Indication, 2014 6
AlgiPharma AS - Pipeline by Stage of Development, 2014 7
AlgiPharma AS - Monotherapy Products in Pipeline, 2014 8
AlgiPharma AS - Phase II, 2014 9
AlgiPharma AS - Preclinical, 2014 10
AlgiPharma AS - Discovery, 2014 11
AlgiPharma AS - Pipeline by Route of Administration, 2014 17
AlgiPharma AS - Pipeline by Molecule Type, 2014 18
AlgiPharma AS - Recent Pipeline Updates, 2014 19